Miracor Medical, an Austrian medical device company, closed a $30 million D funding round, led by Ming Capital of Shenzhen. Miracor is developing an innovative device aimed at limiting damage following a coronary blockage. The company said it would use the new funds to conduct a European test of its device, the PcCSO Impulse System, and begin work for regulatory approval in the US. Because several of the round’s participants are Belgian state investors, Miracor will move to Belgium as part of the funding.
Source: China Biotoday
